Next year, doctors might finally have something new to offer people much-needed drug that can better improve their symptoms without side effects that too often cause them to stop taking their medications.
The latest round of late-stage data on a drug in development by Karuna Therapeutics, released on Monday, reinforces its potential to offer desperately needed progress for a brain disorder that affects about 1% of people in the US.
Karuna's news is a bit of a revival story. One component of the treatment, called xanomeline, has been around since the early 1990s, when scientists at Eli Lilly started exploring its use to treat the cognitive and behavioural symptoms of Alzheimer's disease and, later, schizophrenia.
Small studies suggested the drug could have a marked effect on those symptoms, but it was dropped from development because people could not tolerate its side effects. The problem was that the drug didn't act only on receptors that carry messages between nerve cells in the brain, but interacted with ones throughout the whole body, causing people who took it to get nauseated and vomit.
This story is from the March 24, 2023 edition of Mint Mumbai.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 24, 2023 edition of Mint Mumbai.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Think Tesla Is In Trouble? Pity Even More Its Wannabe EV Rivals
The combined market value of six prominent wannabes hit 400bn in 2021, but today they are worth 65bn
Has The Growth Of Our Economy Translated Into Domestic Jobs?
While the covid shock and other setbacks got in the way, data indicates that employment in India is on a firm recovery path
Financial Sector Reforms Plan To Be Unveiled Post Elections
The govt will cut its stake in five PSBs this fiscal to comply with Sebi’s listing guidelines
Generative AI Is Not Ubiquitous In The Business World-Not Yet
While some AI tools racked up users, some firms are proceeding with caution, or not at all
Wipro’s CEO switch was not about its share price
Shareholder value data does not explain the firm's change on top. In a flux-filled field like infotech, business performance counts for more and Wipro's challenge still seems quite steep
How not to blow a major chunk of your travel budget on visas
Rejection of visas can impact your travel costs, especially when you have to cancel flight and hotel bookings
Wheat output at 106 mt to fall short of govt estimate: Survey
This decline in output comes at a time India confronts rising food inflation
Ghosh won't stay on Bandhan Bank board
Board may even look at appointing an interim CEO post his tenure
Biocon leads Indian charge into weight loss drugs as patents lapse
Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that's expected to touch $100 billion by 2030.
Aakash names Deepak Mehrotra as managing director and CEO
Aakash Educational Services Ltd (AESL), a subA sidiary of embattled startup Byju's, has appointed Deepak Mehrotra as its managing director and chief executive officer.
